oncoJC: Radiation Oncology

On August 23rd, we produced the first in our new series of online Journal Clubs. Dr. med. Andreas Meister from the Kantonsspital Aarau presented the study “Rethinking Strategies for Stage III NSCLC” by Jeffrey Bradley, MD and discussed it with Dr. red. nat. Gerd Lutters, Dr. med. Jürg Heuberger and Prof. Niloy Datta form the Radiation Oncology Department of the Kantonsspital Aarau.

Many thanks to everybody involved and supportive of the project.
Recorded on August 23rd. Technical support: Michael Heuser. Production: Relatris.ch
With the financial support of AMGEN.

How should we integrate new immunotherapies into treatment strategies for lung cancer?

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

Published 10th of July 2013 by http://cancerGRACE.org/

oncoJC: Urogenital Cancer

On April 10th, 2013, our first “all-online” Journal Club was moderated by Dr. med. Richard Cathomas and joined by PD Dr. med. Frank Stenner and Dr. med. Philippe von Burg. The paper discussed was 2-weekly vs. 3-weekly docetaxel to treat castration-resistant prostate cancer: a randomised phase 3 trial by Kellokumpu-Lehtinen et al.; Lancet Oncology 2013;14:117-124 (abstract).

After a short introduction to the paper by Richard Cathomas, the participant discussed the value and the limitations of the finding that a 2-weekly administration of docetaxel leads to comparable results to a 3-weekly scheme, if a change of therapy will be implemented in their clinical work and if so, for which patients.

Please post questions or comments above (leave a reply)  and we will refer them to the discussants.